Although these key players essential for tumor cell proliferation in harsh TME conditions and LYSET invovled in lysosomal biogenesis have been uncovered in the latest studies (Pechincha et al., 2022; Richards et al., 2022), their impact on pan-cancer clinical outcomes remains unknown. This evidence concerns the gene LYSET and neoplasm.